JPWO2021007465A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021007465A5 JPWO2021007465A5 JP2022502022A JP2022502022A JPWO2021007465A5 JP WO2021007465 A5 JPWO2021007465 A5 JP WO2021007465A5 JP 2022502022 A JP2022502022 A JP 2022502022A JP 2022502022 A JP2022502022 A JP 2022502022A JP WO2021007465 A5 JPWO2021007465 A5 JP WO2021007465A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- nucleic acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962872084P | 2019-07-09 | 2019-07-09 | |
US62/872,084 | 2019-07-09 | ||
PCT/US2020/041473 WO2021007465A2 (fr) | 2019-07-09 | 2020-07-09 | Traitement du cancer faisant appel à des formulations pharmaceutiques d'parni ciblées pour réguler à la baisse l'expression de la protéine prdm14 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022545055A JP2022545055A (ja) | 2022-10-25 |
JPWO2021007465A5 true JPWO2021007465A5 (fr) | 2023-07-19 |
Family
ID=74115310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022502022A Pending JP2022545055A (ja) | 2019-07-09 | 2020-07-09 | PRDM14タンパク質の発現をダウンレギュレートする標的化siRNA製剤を使用する癌処置 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220267775A1 (fr) |
EP (1) | EP3996684A4 (fr) |
JP (1) | JP2022545055A (fr) |
CN (1) | CN114727958B (fr) |
WO (1) | WO2021007465A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116113421A (zh) | 2020-05-14 | 2023-05-12 | 阿莱兹精准医疗公司 | 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗 |
CN113616593A (zh) * | 2021-08-23 | 2021-11-09 | 嘉兴学院 | 一种纳米靶向聚合物胶束在制备靶向给药系统中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5219818B2 (ja) * | 2006-09-27 | 2013-06-26 | 今井浩三 | 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット |
WO2011050178A2 (fr) * | 2009-10-21 | 2011-04-28 | Lonnie Bookbinder | Agents thérapeutiques de modulation ciblée de gènes ou protéines prdm |
EP2571987B1 (fr) * | 2010-05-21 | 2017-03-01 | Peptimed, Inc. | Réactifs pour le traitement du cancer |
WO2012061443A2 (fr) * | 2010-11-01 | 2012-05-10 | NanoOncology, Inc. | Compositions d'un système à base de peptides pour le ciblage spécifique de cellules |
JP6683986B2 (ja) * | 2013-07-10 | 2020-04-22 | 国立大学法人 東京大学 | がん幹細胞分子マーカー |
EP3052521A1 (fr) * | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucléotides codant pour un récepteur de lipoprotéines de faible densité |
WO2016065273A1 (fr) * | 2014-10-24 | 2016-04-28 | The University Of Chicago | Domaines de protéines thermo-inductibles à auto-assemblage |
-
2020
- 2020-07-09 EP EP20836336.6A patent/EP3996684A4/fr active Pending
- 2020-07-09 CN CN202080063192.4A patent/CN114727958B/zh active Active
- 2020-07-09 WO PCT/US2020/041473 patent/WO2021007465A2/fr unknown
- 2020-07-09 JP JP2022502022A patent/JP2022545055A/ja active Pending
-
2022
- 2022-01-07 US US17/571,251 patent/US20220267775A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2197885T3 (es) | Uso de inhibidores csf-1. | |
US20230031703A1 (en) | Stabilized hnf4a sarna compositions and methods of use | |
US20240018519A1 (en) | Stabilized saRNA Compositions and Methods of Use | |
MX2011000227A (es) | Composiciones y metodos para inhibir la expresion de genes del receptor de factor de crecimiento por transformacion-beta. | |
CA2692155A1 (fr) | Compositions comprenant un arnsi de egfr humain et leurs procedes d'utilisation | |
KR20100131509A (ko) | Rna 간섭 효과가 높은 2본쇄 지질 수식 rna | |
JP2010502230A (ja) | Sirnaおよび製造方法 | |
CN107530439B (zh) | 用于治疗癌症的对人抗原R表达的siRNA抑制 | |
JP6033218B2 (ja) | がんを治療するための試薬および方法 | |
US20220281911A1 (en) | Oligonucleotide conjugate compositions and methods of use | |
ES2363500T3 (es) | Arn interferente para el gen znfn3a1 como método para inhibir el crecimiento de células cancerosas. | |
WO2012173994A2 (fr) | Formulations de modification de phase de charges utiles d'acide nucléique | |
JP2022545055A (ja) | PRDM14タンパク質の発現をダウンレギュレートする標的化siRNA製剤を使用する癌処置 | |
JPWO2021007465A5 (fr) | ||
JP3289912B2 (ja) | ポリアミノ酸オリゴヌクレオチドキャリヤー | |
WO2011111874A1 (fr) | Arn du type en forme d'haltère et à perméation de membrane cellulaire et son procédé de fabrication | |
KR20240040112A (ko) | 방법 | |
Yin et al. | Asymmetric siRNA targeting the bcl-2 gene inhibits the proliferation of cancer cells in vitro and in vivo | |
US20150329857A1 (en) | Rna interference to activate stem cells | |
EP2064328A2 (fr) | Sensibilisation des cellules de cancer à la thérapie en utilisant le sina visant des gènes des régions 1p et 19q chromosomiques | |
JPWO2019181305A1 (ja) | snoRNAの発現抑制剤を有効成分とするがん増殖抑制剤 | |
WO2014169087A2 (fr) | Traitement de l'atrophie musculaire spinale proximale | |
KR101595152B1 (ko) | Tctp-ptd를 포함하는 유전자 전달체 | |
US11655474B2 (en) | Suppression of pathological angiogenesis by inhibition of NR2F6 | |
US20240150764A1 (en) | Therapeutic splice-switching oligonucleotides for cancer |